1. Immunology and Inflammation

Reversible promoter methylation determines fluctuating expression of acute phase proteins

  1. Shi-Chao Zhang
  2. Ming-Yu Wang
  3. Jun-Rui Feng
  4. Yue Chang
  5. Shang-Rong Ji  Is a corresponding author
  6. Yi Wu  Is a corresponding author
  1. MOE Key Laboratory of Cell Activities and Stress Adaptations, School of Life Sciences, Lanzhou University, China
  2. MOE Key Laboratory of Environment and Genes Related to Diseases, School of Basic Medical Sciences, Xi'an Jiaotong University, China
https://doi.org/10.7554/eLife.51317
Share this article
Cite this article
  1. Shi-Chao Zhang
  2. Ming-Yu Wang
  3. Jun-Rui Feng
  4. Yue Chang
  5. Shang-Rong Ji
  6. Yi Wu
(2020)
Reversible promoter methylation determines fluctuating expression of acute phase proteins
eLife 9:e51317.
https://doi.org/10.7554/eLife.51317
  2. Download BibTeX
  3. Download .RIS

Abstract

Acute phase reactants (APRs) are secretory proteins exhibiting large expression changes in response to proinflammatory cytokines. Here we show that the expression pattern of a major human APR, that is C-reactive protein (CRP), is casually determined by DNMT3A and TET2-tuned promoter methylation status. CRP features a CpG-poor promoter with its CpG motifs located in binding sites of STAT3, C/EBP-β and NF-κB. These motifs are highly methylated at the resting state, but undergo STAT3- and NF-κB-dependent demethylation upon cytokine stimulation, leading to markedly enhanced recruitment of C/EBP-β that boosts CRP expression. Withdrawal of cytokines, by contrast, results in a rapid recovery of promoter methylation and termination of CRP induction. Further analysis suggests that reversible methylation also regulates the expression of highly inducible genes carrying CpG-poor promoters with APRs as representatives. Therefore, these CpG-poor promoters may evolve CpG-containing TF binding sites to harness dynamic methylation for prompt and reversible responses.

Introduction

Acute phase reactants (APRs) are liver-produced plasma proteins constituting an integral part of innate defense (Gabay and Kushner, 1999; Medzhitov, 2007). They are defined by a substantial change (>25%) of their plasma concentrations in response to inflammation. IL-6 (Kopf et al., 1994) and IL-1β (Zheng et al., 1995) are chief inducers of APR expression through activation of STAT3, NF-κB and C/EBP in hepatocytes (Bode et al., 2012; Quinton et al., 2012; Poli, 1998). C-reactive protein (CRP) is the first APR to be discovered, whose plasma concentrations at baseline are less than 2–3 µg/ml, but can rapidly increase up to 1000-fold upon infection or tissue injury; the heightened levels of CRP, however, return to the baseline with the resolution of inflammation (Pepys and Hirschfield, 2003; Du Clos, 2013; Pathak and Agrawal, 2019). The mechanisms of CRP induction have been thoroughly examined by reporter assays and truncation analysis. A region of ~220 bp in the proximal promoter of CRP that contains (nonconical) binding sites for STAT3, NF-κB and C/EBP-β is identified to be sufficient to mediate CRP induction by IL-6 and IL-1β (Singh et al., 2007; Young et al., 2008; Figure 1A).

Figure 1
Download asset Open asset
Methylation level of CRP promoter is inversely associated with expression.

(A) Schematic illustration of CRP promoter in which SNP rs3091244, CpG motifs and TF binding sites are indicated. (B) Methylation levels of CRP promoter (−550 ~ 1 bp) in pooled normal human tissues adjacent to tumors (five liver, eight colon, 10 esophagus, 10 rectum and 10 gaster) were determined by bisulfite cloning sequencing. (C) Methylation levels of CRP promoter in normal human tissues were retrieved from available GEO datasets generated by whole-genome bisulfite sequencing: Liver 01-GSM916049, Liver 02-GSM1716965, Adipose-GSM1120331, Adrenal-GSM1120325, Aorta-GSM1120329, Esophagus-GSM983649, Gaster-GSM1120333, Lung-GSM983647, Ovary-GSM1120323, Muscle-GSM1010986, Atrium-GSM1120335, Colon-GSM983645, Spleen-GSM983652, Thymus-GSM1120322 (Gene Expression Omnibus database). The bisulfite sequencing tracks of CRP promoter (left; the height of the black bars represents percentage of DNA methylation) and pooled analysis (right) are shown. (D) Methylation levels of CRP promoter in rabbit tissues were determined by bisulfite cloning sequencing. Liver is the major organ expressing CRP in both humans and rabbits. Accordingly, the methylation levels of CRP promoter are lower in normal liver tissues than in other tissues. (E) Levels of CRP expression (left) and promoter methylation (right) in tumor versus normal tissues from human livers (n = 5) were determined by q-PCR and bisulfite cloning sequencing, respectively. Liver tumors exhibit higher levels of CRP expression but lower levels of promoter methylation than adjacent normal liver tissues. *p<0.05 (paired t-test). (F) Bisulfite cloning sequencing of −286C versus −286A alleles of CRP promoter in Hep3B cells at resting (Vehicle treated) or induced states (IL-6 and IL-1β treated). −286A allele was less methylated than −286C allele at both states. (G) IL-6 (10 ng/ml) and IL-1β (1 ng/ml) treatment induced CRP expression (left) and promoter demethylation (right) in Hep3B cells, while withdraw of these cytokines led to a quick drop of CRP expression and promoter re-methylation. The result of one representative experiment is shown.

Intriguingly, a promoter SNP (rs3091244) associated with plasma levels of CRP is located at 286 bp upstream the transcription start site (Szalai et al., 2005; Zacho et al., 2008; Allin et al., 2010). This SNP does not exist in binding sites of transcription factors (TFs) critical to CRP expression. Rather, the major −286C allele constitutes a CpG motif, at which DNA methylation frequently occurs; whereas the minor alleles of −286A/T disrupt the CpG motif and are associated with enhanced CRP expression. Beside the −286CpG, there are only four additional CpGs within the proximal promoter of CRP. Importantly, two of those CpGs are located at the binding sites of STAT3 and NF-κB/C/EBP-β (Figure 1A). Given that promoter methylation affects TF recruitment (Hu et al., 2013; Yin et al., 2017) and contributes to gene silencing (Jones, 2012; Wu and Zhang, 2014; Dor and Cedar, 2018; Luo et al., 2018; Blattler and Farnham, 2013), it is notable that levels of promoter methylation and expression of CRP appear to be negatively associated albeit with undefined causality (Wang et al., 2014). In the present study, we demonstrate that the expression pattern of CRP is causally determined by reversible promoter methylation, and that this regulation may also apply to highly inducible genes with CpG-poor promoters.

Results

Promoter methylation is inversely associated with CRP expression

To determine whether promoter methylation affects CRP expression, we first compared methylation levels of CRP promoter in different human tissues. CRP is expressed predominantly, if not solely, by the liver (Pepys and Hirschfield, 2003; Du Clos, 2013). Accordingly, methylation levels of CRP promoter in normal liver tissues were much lower than that in other tissues (Figure 1B). Analysis of published bisulfite sequencing datasets also confirmed that CRP promoter was most demethylated in the liver (Figure 1C). Similar results were further obtained in rabbits (Figure 1D), wherein CRP exhibits a comparable expression pattern as in humans. Moreover, malignant liver tissues expressed more CRP than adjacent normal tissues, and they were also less methylated at CRP promoter (Figure 1E). These data together reveal an inverse association between levels of promoter methylation and CRP expression across different tissues or cell types.

Hepatic Hep3B cell line is a conventional model to investigate APR expression (Singh et al., 2007; Young et al., 2008). CRP promoter in Hep3B cells harbors distinct alleles at the −286 position, with −286C on one allele and −286A on the other. Intriguingly, in addition to lacking the −286CpG, all other promoter CpGs on the −286A allele were much less methylated than that on the −286C allele at the resting state (Figure 1F). Such an allelic imbalance of promoter methylation was further reinforced at the induced state. Notably, the induction of CRP by IL-6 and IL-1β was accompanied by prominent promoter demethylation (Figure 1G). Following washout of the cytokines, however, both the expression and the promoter methylation of CRP were rapidly recovered. By contrast, the methylation level of a 5’ UTR CpG remained constant during the entire time course. Therefore, levels of promoter methylation and CRP expression are also specifically and dynamically associated in the same cell type.

Promoter methylation causally determines CRP expression

To clarify whether the observed association is causal, we directly modulated methylation levels of CRP promoter and examined its consequence on expression. Treating Hep3B cells with 5-aza or RG108 to inhibit DNA methylation significantly enhanced CRP expression at the resting state, but showed little effect at the induced state (Figure 2A; Figure 2—figure supplement 1) wherein CRP promoter also underwent active demethylation (Figure 1G). Nevertheless, 5-aza could moderately rescue the induced expression of CRP when STAT3 or NF-κB was inhibited (Figure 2B and C), hinting for their involvement in active demethylation of CRP promoter. Moreover, in vitro methylation before transfection markedly suppressed the reporter activity of CRP promoter in Hep3B cells (Figure 2D). This suppression, however, was partially reversed by mutating individual CpG motifs, and was completely absent with a CpG-null mutant of CRP promoter. These results suggest that promoter methylation inhibits, whereas its demethylation enhances CRP expression, thus supporting a causal association.

Figure 2 with 1 supplement see all
Download asset Open asset
Methylation levels of CRP promoter causally determines expression.

(A) The effects of DNA methylation inhibitor RG-108 (25 μM, 24 hr) or 5-aza (5 μM, 12 hr) on CRP expression in Hep3B cells at the resting or induced state (n = 3). These inhibitors enhanced the resting but not the induced expression of CRP. At the induced state, the defective CRP expression caused by STAT3 (s31-201, 30 μM, 24 hr) (B) or NF-κB inhibition (BAY11-7082, 2 μM, 24 hr) (C) was partially reversed by 5-aza (5 μM, 24 hr) (n = 3). (D) In vitro vector methylation markedly inhibited reporter activities of wildtype CRP promoter (WT) following transfection into Hep3B cells (n = 3). Mutating individual CpG motif partially reversed this inhibition. As the control, in vitro vector methylation did not affect reporter activities of a CpG-null version of CRP promoter. Data are presented as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001 (two-tailed t-test).

CpG methylation and demethylation are mediated by DNA methyltransferases (DNMTs) and ten-eleven translocations (TETs), respectively (Jones, 2012; Wu and Zhang, 2014; Dor and Cedar, 2018; Luo et al., 2018). A causal association with promoter methylation would therefore predict that the expression of CRP should also be regulated by DNMTs and/or TETs. Indeed, RNAi screening revealed that knockdown (KD) of DNMT3A enhanced (Figure 3A), whereas KD of TET2 reduced CRP expression in Hep3B cells (Figure 3B). Knockout (KO) of DNMT3A (Figure 3C) or TET2 (Figure 3D) with Cas9 yielded consistent but more pronounced effects. Importantly, DNMT3A/TET2 KD or KO showed expected effects on CRP promoter methylation and on their own expression (Figure 3—figure supplements 1 and 2) without upregulating TFs critical to CRP induction (Figure 3—figure supplement 3). On the other hand, the overexpression of DNMT3A reduced, while the overexpression of TET2 enhanced CRP expression (Figure 3E). These results together identify DNMT3A and TET2 as the negative and positive regulators of CRP expression, respectively, thus reinforcing the notion that CRP expression is causally determined by promoter methylation.

Figure 3 with 3 supplements see all
Download asset Open asset
DNMT3A and TET2 regulate CRP expression.

CRP expression in Hep3B cells with DNMT (A) or TET (B) knockdown by control (mirNT) or target-specific miRNA (n = 3). (C) CRP expression in Hep3B cells with co-transfected Cas9 and sgRNAs targeting exon 14 (sgDNMT3A-1) or 2 (sgDNMT3A-2) of DNMT3A (n = 3). (D) CRP expression in Hep3B cells with co-transfected Cas9 and sgRNAs targeting exon 3 (sgTET2-1) or 7 (sgTET2-2) of TET2 (n = 3). (E) CRP expression in Hep3B cells with overexpressed DNMT3A or TET2 (n = 3). CRP expression in Hep3B cells with co-transfected catalytic domain of DNMT3A (F) or TET2 (G) fused to dCas9 and sgRNAs targeting CRP promoter (n = 3). The results identified DNMT3A and TET2 as the negative and positive regulators of CRP expression, respectively. Selective targeting of DNMT3A or TET2 to CRP promoter by dCas9 only regulated the expression of CRP, but did not affect that of serum amyloid A (SAA; a major human APR) or serum amyloid P component (SAP, a paralog of CRP). Data are presented as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001 (two-tailed t-test).

Of note, inhibitor treatment or DNMT3A/TET2 manipulations would all affect the methylation status of entire genome. To exclude any indirect effect caused by global manipulation, we specifically modulated the methylation levels of CRP promoter by dCas9-mediated targeting of the catalytic domains of DNMT3A or TET2. Enforced methylation of CRP promoter by DNMT3A-dCas9 reduced the expression of CRP in Hep3B cells, but showed little effect on that of serum amyloid A (SAA, another major human APR) and serum amyloid P component (SAP, a paralog of CRP) (Figure 3F). By contrast, enforced demethylation of CRP promoter by TET2-dCas9 only selectively enhanced the expression of CRP (Figure 3G). We thus conclude that DNMT3A and TET2-tuned methylation status of CRP promoter constitutes a key part of the regulatory mechanism that causally determines the expression.

Promoter methylation of CRP dictates strength of TF recruitment

We next asked whether the promoter methylation-mediated regulation could be conferred by influencing TF recruitment. Indeed, IL-6 and IL-1β-induced demethylation of CRP promoter (Figure 1G) was paralleled by markedly enhanced recruitment of STAT3, NF-κB p50 and C/EBP-β (Figure 4A; Singh et al., 2007; Young et al., 2008). Moreover, in vitro methylation substantially reduced the recruitment of those TFs to vectors containing CRP promoter after transfection into Hep3B cells (Figure 4B). The −53CpG and −108CpG are at the binding sites of p50/C/EBP-β, and STAT3, respectively (Figure 1A). Accordingly, site-specific methylation of −53CpG selectively prevented the recruitment of p50 and C/EBP-β to CRP promoter, while site-specific methylation of −108CpG only inhibited the recruitment of STAT3 (Figure 4C). These CpG motifs at TF binding sites may thus act as rheostats with their methylation turning down the recruitment of critical TFs, resulting in reduced expression.

Figure 4
Download asset Open asset
Methylation levels of CRP promoter affect TF recruitment.

The recruitment of TFs to CRP promoter in Hep3B cells was analyzed by ChIP. (A) The recruitment of STAT3, p50 and C/EBP-β to CRP promoter were all markedly enhanced at the induced versus resting state (n = 3). (B) In vitro vector methylation decreased the recruitment of STAT3, p50 and C/EBP-β to a vector containing CRP promoter at the induced state (n = 3). (C) Site-specific methylation at −53CpG inhibited the recruitment of p50 and C/EBP-β, whereas methylation at −108CpG inhibited the recruitment STAT3 to the vector containing CRP promoter at the induced state (n = 3). Data are presented as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001 (two-tailed t-test).

Dynamic crosstalk among TFs and promoter methylation in induced expression of CRP

We further examined how TF recruitment and promoter methylation dynamically orchestrate to regulate the induced expression of CRP. IL-6 and IL-1β induced two waves of CRP expression: the first wave lasted from 0 to 6 hr yielding the minor peak, while the second lasted from 12 to 24 hr yielding the major peak (Figure 5A). The recruitment of STAT3 occurred during the first wave and saturated at 3 hr before the minor peak (Figure 5B). By contrast, the recruitment of p50 was more evident during the time lag between the two waves (Figure 5C). The recruitment of C/EBP-β, whose action depends on p50 (Cha-Molstad et al., 2000; Kramer et al., 2008; Agrawal et al., 2001), however, steadily rose till 12 hr (Figure 5D). These would suggest that the first wave of induced CRP expression is driven by early recruited STAT3, which licenses the late recruitment of p50 that synergizes with C/EBP-β to drive the second wave. As such, STAT3 is likely the pioneer TF that binds methylated CRP promoter to initiates induction and primes demethylation.

Figure 5
Download asset Open asset
TF recruitment and promoter methylation dynamically crosstalk to regulate the induced expression of CRP.

CRP expression (A) and promoter recruitment of STAT3 (B), p50 (C) and C/EBP-β (D) in Hep3B cells at the induced state without (WT) or with co-transfected Cas9 and sgRNA targeting exon 14 of DNMT3A (n = 3) or targeting exon 3 of TET2 (n = 2) over time. TET2 KO markedly reduced the induction of CRP, and almost abrogated the promoter recruitment of p50 and C/EBP-β. The recruitment of STAT3 to CRP promoter was still evident in TET2 KO cells. DNMT3A KO resulted in a stronger amplitude and altered dynamics of CRP induction. The recruitment to CRP promoter was enhanced for all the three TFs in DNMT3A KO cells, whereas the timing of recruitment was altered only for p50. (E) CRP expression in Hep3B cells treated with vehicle, 1 ng/ml IL-1β, 10 ng/ml IL-6 or their combination for 48 hr (n = 3). As IL-1β is unable to induce IL-6 production in Hep3B cells (Kramer et al., 2008), the effects of STAT3 and p50 can be largely dissociated by treating cells with one single cytokine (Kramer et al., 2008; Ganapathi et al., 1991; Ganapathi et al., 1988). IL-1β could not induce CRP expression, suggesting p50 is not required for the first wave of CRP induction. (F) Methylation levels of CRP promoter in Hep3B cells at the induced state treated without (Vehicle) or with inhibitors of STAT3 (30 μM s31-201) or NF-κB (2 μM BAY11-7082) for 24 hr. (G) Ratios of methylation levels on −286C versus −286A alleles in Hep3B cells at the induced state treated with the NF-κB inhibitor (2 μM BAY11-7082) for 24 hr. Methylation levels (H) and allelic methylation of CRP promoter (I) in Hep3B cells expressing a control or a C/EBP-β vector at the resting state. C/EBP-β overexpression showed no effect on methylation status of CRP promoter. The result of one representative experiment is shown. (J) CRP expression in Hep3B cells with or without C/EBP-β overexpression under the indicated conditions for 48 hr (n = 3). (K) CRP expression in Hep3B cells without (sgNT) or with C/EBP-β KO (sgC/EBP-β) following induction with 10 ng/ml IL-6 and 1 ng/ml IL-1β for 48 hr (n = 3). The dramatic effects of C/EBP-β KO or overexpression suggest that this TF is the major effector that respond to promoter methylation status and determine the amplitude of CRP expression. (L) A schematic illustration of how TF recruitment and promoter methylation dynamically orchestrate to regulate the induction of CRP. Data are presented as mean ± SEM. **p<0.01, ***p<0.001 (two-tailed t-test).

In line with the above suggestion, STAT3 was the only TF showing appreciable early recruitment to CRP promoter upon enforced DNA methylation by TET2 KO (Figure 5B–D). This indicates that STAT3 can nevertheless be recruited to CRP promoter even when heavily methylated, consistent with the observations that vector binding of STAT3 was least sensitive to methylation (Figure 4B and C). This also indicates that STAT3 can act largely independent of p50 and C/EBP-β to drive CRP induction, albeit with a markedly reduced amplitude (Figure 5A). Indeed, the sole activation of STAT3 in wildtype cells was able to induce CRP expression to a level comparable to that of the minor peak, whereas the sole activation of NF-κB was completely ineffective (Figure 5E). Despite that, NF-κB inhibition (with intact STAT3) at the induced state resulted in an even stronger methylation of CRP promoter (Figure 5F) and a reversal of allelic imbalance (Figures 5G and 1F). Therefore, promoter demethylation requires p50 that acts downstream of STAT3.

Interestingly, enforced DNA demethylation by DNMT3A KO not only tripled CRP expression during the entire course of induction, but eliminated the time lag between the two waves (Figure 5A). The augmented amplitude can be explained by the enhanced recruitment of the three TFs, while the altered dynamics may correspond to the shifted timing of p50 recruitment (Figure 5B–D). As such, p50 selectively recruited during the time lag could be responsible for promoter demethylation to prime the second wave. Accordingly, C/EBP-β appears to be the major effector that responds to promoter demethylation: its overexpression did not demethylate CRP promoter (Figure 5H and I), but when combined with blockage of DNA methylation, it drove the resting expression of CRP to a level approaching to that induced by IL-6 and IL-1β (Figure 5J). C/EBP-β KO, however, lowered the induced expression of CRP by ~70% (Figure 5K). These together demonstrate a stepwise induction of CRP where TFs and promoter methylation dynamically orchestrate (Figure 5L).

Reversible methylation regulates expression of genes with CpG-poor promoters

Having established the regulation of CRP expression by reversible promoter methylation, we wondered whether the same regulation can be applied to other APRs. Indeed, SAA behaved similarly as CRP. Treating Hep3B cells with IL-6 and IL-1β resulted in a drastic increase in the expression of SAA (Figure 6A) and a reduction in methylation levels of its promoter (Figure 6B). These were, however, quickly recovered following cytokine withdraw. By contrast, neither the expression nor the promoter methylation of SAP was affected by treatment or withdraw of IL-6 and IL-1β (Figure 6A and C). Moreover, DNMT3A KO also markedly enhanced the induced expression of SAA, but barely affected that of SAP (Figure 6D). These results suggest that reversible promoter methylation may be a general mechanism underlies the induction of APRs.

Figure 6
Download asset Open asset
Reversible methylation regulates the induced expression of SAA.

Hep3B cells were treated with 10 ng/ml IL-6 and 1 ng/ml IL-1β for 48 hr, and then cultured in the absence of cytokine for 36 hr. (A) The expression levels of CRP, SAA and SAP (n = 3). (B) The methylation levels of SAA promoter. (C) The methylation levels of SAP promoter. The expression and methylation levels of SAA were inversely, and dynamically coupled. The expression of SAP was not induced, and methylation levels of its promoter did not change over time. The result of one representative experiment is shown. (D) The expression levels of CRP (upper), SAA (middle) and SAP (lower) in the parental or a clone of DNMT3A KO Hep3B cells at the resting or induced state (n = 3). DNMT3A KO enhanced the expression of CRP and SAA, but showed only marginal effects on that of SAP. Data are presented as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001 (two-tailed t-test).

The promoters of most mammalian genes contain a high frequency (observed number/expected number >0.6) of CpGs termed CpG islands (CGIs) that are resistant to DNA methylation (Saxonov et al., 2006). The CpG frequency of CRP promoter, however, is exceptionally low (~0.23). Interestingly, a low CpG frequency appears to be general feature of APR promoters (Figure 7A). We then extended our analysis to genes with CpG-poor promoters. In Hep3B cells treated with IL-6 and IL-1β, strongly induced genes tended to manifest lower CpG ratios in their promoters (Figure 7B; Figure 7—figure supplement 1). Similar observations were also made in livers of mice undergoing turpentine-induced acute inflammation (Figure 7C). Importantly, genes with CpG-poor promoters showed significantly stronger changes in both expression and promoter methylation (Figure 7D and E; Figure 7—figure supplement 1). Therefore, dynamic methylation may also regulate the expression of highly inducible genes with CpG-poor promoters.

Figure 7 with 1 supplement see all
Download asset Open asset
Genes with CpG-poor promoters are preferentialy demethylated and induced in acute inflammation.

(A) Both the numbers and ratios of promoter CpG are significantly lower in APRs (n = 34) than in cytokines (n = 117), housekeeping genes (n = 425) or all genes of HG19 (n = 20180). (B) Hep3B cells were treated with 10 ng/ml IL-6 and 1 ng/ml IL-1β for 24 hr, and gene expression profiles were determined by RNA-seq. Genes with larger expression changes exhibited lower promoter CpG ratios. There are 10979, 2130, 454, and 121 genes in <2 fold, 2 ~ 5 fold, 5 ~ 15 fold, and >15 fold categories, respectively. Mouse liver tissues were collected at the resting or turpentine-induced state. Their transcriptome and methylome were then determined and compared. (C) Genes whose expression changed by over 2-fold between the two states exhibit lower promoter CpG densities. There are 12338, 2876, 444, and 51 genes in <2 fold, 2 ~ 5 fold, 5 ~ 15 fold, and >15 fold categories, respectively. With the increase in promoter CpG density, genes show markedly reduced changes in levels of their expression (D) (There are 3096, 3903, 3903, and 3907 genes in Q1, Q2, Q3, and Q4 categories, respectively) and promoter methylation (E) (There are 3745, 3738, 3741, and 3742 genes in Q1, Q2, Q3, and Q4 categories, respectively). Statistical analysis was performed using K-S test.

Discussion

Though TFs critical to CRP expression have been identified, how their actions are coordinated remains unclear. This study demonstrates a previously unrecognized, epigenetic mechanism wherein methylation status of CRP promoter responds to and further modifies the effects of distinct TFs. At the induced state, the pioneered binding of STAT3 to CRP promoter in hepatocytes drives a minor wave of induction, and further licenses the subsequent recruitment of NF-κB p50. The two TFs probably work together to tip the balance of TET2 and DNMT3A at CRP promoter, leading to its demethylation. As significant cell proliferation was not noted, the methylated cytosine might be eventually removed by base excision repair mechanism (Wu and Zhang, 2014). Consequently, the demethylated promoter enhances the recruitment of C/EBP-β to drive the major wave of CRP induction. During the recovery phase, however, the loss of activated STAT3 and p50 results in a rapid remethylation of CRP promoter and termination of induction. At the resting state, however, the relatively hypomethylated promoter of CRP in the liver versus other tissues likely favors C/EBP-β recruitment, contributing to its tissue-specific, basal expression. These may form the basis for CRP, a putative pattern recognition receptor (Du Clos, 2013; Bottazzi et al., 2010), to constitute an integral part of immune surveillance in both homeostasis and inflammation.

In addition to CRP, we further show that reversible methylation also appears to be involved in regulation of highly inducible genes carrying CpG-poor promoters with APRs as representatives. In this regard, it is worth noting that DNA methylation is a relative stable epigenetic modification (Wu and Zhang, 2014). Though dynamic changes in global or local DNA methylation status have been demonstrated in processes of development, aging and disease, these (gradual) changes, once occurred, are largely persistent or irreversible (Wu and Zhang, 2014; Dor and Cedar, 2018; Luo et al., 2018; Halder et al., 2016; Sellars et al., 2015; Domcke et al., 2015; Flavahan et al., 2016; Dmitrijeva et al., 2018; Koch et al., 2018; Horvath and Raj, 2018) with its causality in determining gene expression even being questioned (Bestor et al., 2015). There are, however, only rare cases where the expression of specific genes, such as pS2 (Métivier et al., 2008; Kangaspeska et al., 2008) and IL-10 (Hwang et al., 2018), is regulated by rapid and reversible changes in DNA methylation. Our findings here identify an important scenario in which reversible promoter methylation plays a critical role in determining the expression pattern of a class of proteins featured by CpG-poor promoters in response to inflammatory stimuli.

Acute changes in DNA methylation have also been analyzed at a genome-wide scale in previous studies. One study examined mouse neurons activated by electroconvulsive stimulation, and found that methylation changes were preferentially occurred in CpG-poor regions (Guo et al., 2011). Though promoters were underrepresented in these regions, their methylation changes were nevertheless modestly anticorrelated with gene expression (Guo et al., 2011). Such CpG content-dependent changes in DNA methylation, however, were not observed in another study examining neurons activated by contextual learning (Halder et al., 2016). Moreover, DNA methylation changes in human dendritic cells following infection rarely occurred at promoters (Pacis et al., 2019; Pacis et al., 2015), and were claimed to be a consequence of gene expression (Pacis et al., 2019). Those findings thus argue that the regulation of reversible methylation on inducible expression of genes with CpG-poor promoters may be context-dependent, and that rigorously controlled case study should be integrated into genome-wide investigation to conclude on causality.

Interestingly, genes showing inducible expression in macrophages activated by endotoxin have been classified into two groups: nucleosome remodeling-independent genes with CpG-rich promoters, and nucleosome remodeling-dependent genes with CpG-poor promoters (Ramirez-Carrozzi et al., 2009). Despite their distinct requirements for SWI/SNF complexes, preassembled Pol II and new protein synthesis, both groups of genes exhibit a single-wave kinetics of induction (Ramirez-Carrozzi et al., 2009; Hargreaves et al., 2009; Ramirez-Carrozzi et al., 2006). This is in contrast with CRP and probably other major APRs, which show a two-wave kinetics of induction with the second wave licensed by promoter demethylation. However, nucleosome remodeling might still act downstream in the second wave, as C/EBP-β has recently been shown to promote CRP expression by recruiting BRG1 via MKL1 (Fan et al., 2019). Conversely, promoter methylation could also contribute to inducible expression of nucleosome remodeling-dependent genes in macrophages by directly regulating TF recruitment (Hu et al., 2013; Yin et al., 2017; Thomas et al., 2012).

Despite that most CpGs in mammalian promoters not associated with CGIs are usually methylated (Wu and Zhang, 2014; Luo et al., 2018), TETs and DNMTs can nevertheless mediate active demethylation and de novo methylation, respectively. This indicates that the methylation status of part of the genome may depend on the balance of the two types of enzymes (Jones, 2012; Wu and Zhang, 2014; Dor and Cedar, 2018; Luo et al., 2018; Blattler and Farnham, 2013). Cellular signaling able to tip the balance of TETs and DNMTs could thus represent a regulatory mechanism that finely and reversibly tunes the expression of certain genes in response to environmental cues. In case of CRP, DNMT3A and TET2 appear to be involved in the regulation. Though the mechanism of TF-induced local demethylation is not fully understood (Luo et al., 2018), TFs including NF-κB and EGR1 have been reported to evoke DNA demethylation in neurons (Jarome et al., 2015) for example by recruiting TET1 (Sun et al., 2019). Future study is warranted to elucidate how TFs regulate the balance of TETs and DNMTs and to discover scenarios where regulation by reversible DNA methylation plays a prominent role.

Materials and methods

Determination of promoter methylation level

Request a detailed protocol

Frozen tumor/normal tissue sample pairs were obtained from the tissue bank of Gansu Cancer hospital. Genomic DNA samples extracted from tissues or Hep3B cells were bisulfite-converted and recovered using EpiTect Bisulfite Kit (QIAGEN, Hamburg, Germany; catalog number: 59104; lot number: 142338839, 145038568, 148214306, 151030901) according to the manufacturer’s instructions. Samples were then amplified with SureStart Taq DNA Polymerase (Agilent Technologies, Santa Clara, CA; catalog number: 600282; lot number: 0006129848). The primer sequences used were: human CRP (Forward: 5’-GTAGGTGTTGGAGAGGTAGTTATTA-3’; Reverse: 5’-ATTTATATCCAAAACAATAAAAAAATTTAC-3’); rabbit CRP (Forward: 5’-ATGTTAGAGTTGAAGGTGTTGGAGATA-3’; Reverse: 5’-AAATACTAAAAATCCTACATCCCTTACCTC-3’); human SAA (Forward: 5’-GTTTTTATTTTATATTTTTTAGTAG-3’; Reverse: 5’-TAATACTAATCTATACTATAACTAAACTAC-3’); human SAP (Forward: 5’-AAGAAAGAAAAGGTTTTGTTTTTA-3’; Reverse: 5’-ATTTTCCAAATCTACCTCCTAAC-3’)). Subsequent cloning and sequencing were performed as described (Varley et al., 2009). The experiments conformed to the Guide for the Care and Use of Laboratory Animals published by NIH, and were conducted according to the protocols approved by the Ethics Committee of Animal Experiments of Xi’an Jiaotong University and Lanzhou University (2016–064 and A201307050027).

Determination of gene expression

Request a detailed protocol

Human hepatocellular carcinoma cell line Hep3B were obtained from cell bank of Chinese Academy of Sciences (Shanghai, China). Hep3B cells were cultured in MEM media (Sigma-Aldrich, St. Louis, MO; catalog number: M0643; lot number: SLBF6418, SLBM7544V) containing 10% FBS (Biological industries, Beit Haemek, Israel; catalog number: 04-001-1A; lot number: 1418110). Cells were tested for mycoplasma and have been authenticated by Cel-ID (Mohammad et al., 2019) using RNA-seq: their correlation (R2) to Hep3B cells (G28888.Hep_3B2.1.7.3) in Cancer Cell Line Encyclopedia project is 0.92 (p<10−24). Total RNA was extracted with RNAiso Plus reagent (Takara, Shiga, Japan; catalog number: 9108, 9109; lot number: 2270A, AA4102-1, AA6201-1, AA3101-1). cDNA was synthesized from 1 μg total RNA using reverse transcriptase M-MLV (Takara; catalog number: 2641B; lot number: AG70412A), Oligo d(T)15 Primers (Takara; catalog number: 3805; lot number: T1301BA), dNTP mixture (Takara; catalog number: 4019; lot number: B4101A), and recombinant ribonuclease inhibitor (Takara; catalog number: 2313B; lot number: K8101GA). Gene expression was determined with quantitative PCR (q-PCR) using SYBR Premix Ex Taq II (Takara; catalog number: RR820A; lot number: AK7602) in a CFX96 Real-Time PCR Detection System (Bio-rad, Hercules, CA). The gene expression levels were normalized to that of ACTB. The primer sequences used were: human CRP (Forward: 5’-GGAGCAGGATTCCTTCGGT-3’; Reverse: 5’-CACTTCGCCTTGCACTTCAT-3’); human SAA (Forward: 5’-GTGATCAGCGATGCCAGAGAGA-3’; Reverse: 5’-CCAGCAGGTCGGAAGTGATTG-3’); human SAP (Forward: 5’-CTTGATCACACCGCTGGAGAAG-3’; Reverse: 5’-CTTGGGTATTGTAGGAGAAGAGGCTG-3’); human ACTB (Forward: 5’-CGTGGACATCCGCAAAGAC-3’; Reverse: 5’- CTCAGGAGGAGCAATGATCTTGA-3’).

Gene expression profiles of Hep3B cells with or without IL-6 and IL-1β treatment for 24 hr were determined with RNA sequencing services provided by GENEWIZ (South Plainfield, NJ). Transcriptome and methylome of C57BL/6 mouse liver tissues at the resting or turpentine-induced state were determined with RNA sequencing and whole genome bisulfite sequencing services (WGBS) provided by GENEWIZ. All RNA-seq and WGBS data have been deposited in GEO under accession code GSE146797.

Where appropriate, Hep3B cells were treated with 10 ng/ml rhIL-6 (R and D Systems, Minneapolis, MN; catalog number: 206-IL; lot number: OJZ1716061), 1 ng/ml rhIL-1β (R and D System; catalog number: 201-LB; lot number: AD1515091), 5-Azacytidine (5-aza; 5 µM, 12 hr; DNA methylation inhibitor) (Sigma-Aldrich; catalog number: A2385; lot number: SLBL4994V), RG108 (25 µM, 24 hr; DNA methylation inhibitor) (Selleck Chemicals, Houston, TX; catalog number: S2821; lot number: 02), BAY11-7082 (2 µM, 24 hr; NF-κB inhibitor) (Selleck Chemicals; catalog number: S2913; lot number: 01), S31-201 (30 µM, 24 hr; STAT3 inhibitor) (Selleck Chemicals; catalog number: S1155; lot number: 02) or Stattic (5 µM, 24 hr; STAT3 inhibitor) (Selleck Chemicals; catalog number: S7024; lot number: 01).

Modulation of DNA methylation regulators

Request a detailed protocol

For knockdown, targeting sequences were synthesized (GENEWIZ), and cloned into pcDNA6.2-GW/EmGFP-miR vector (Invitrogen, Carlsbad, CA; catalog number: K4935-00). The targeting sequences were: DNMT1 (#1 5’-GATTTGGAAAGAGACAGCTTA-3’; #2 5’-CAACAGAGGACAACAAGTTCA-3’); DNMT3A (#1 5’-GGTGTGTGTTGAGAAGCTGAT-3’; #2 5’-GAATTTGACCCTCCAAAGGTT-3’); DNMT3B (#1 5’-GGTTTGGCGATGGCAAGTTCT-3’; #2 5’-CGAGAACAAATGGCTTCAGAT-3’); TET1 (#1 5’-CATGCAAGGCCTTCCAGATTA-3’; #2 5’-AGAGAACAGCCAGTTTGCTTA-3’); TET2 (#1 5’-GTGTAGGTAAGTGCCAGAAAT-3’; #2 5’-CATGGCGTTTATCCAGAATTA-3’); TET3 (#1 5’-CCTTTATGACTTCCCTCAGCG-3’; #2 5’-CCAGTTGATGGACCTGTTCCA-3’). For overexpression, coding sequence of target genes were cloned into pcDNA3.1 vector (Invitrogen; catalog number: V795-20). Vectors were transfected into Hep3B cells with ViaFect Transfection Reagent (Promega, Madison, WI; catalog number: E4982; lot number: 0000251076, 0000136819). 48 hr later, gene expression was determined with q-PCR.

For Cas9-mediated knockout (Ran et al., 2013), targeting sequences corresponding to sgRNAs were synthesized (GENEWIZ), and cloned into pSpCas9(BB)−2A-Puro (PX459) v2.0 vector (Addgene, Cambridge, MA; catalog number: 62988). The targeting sequences were: DNMT3A (#1 5’-GGACCTCTTGGTGGGGCCGG-3’ against exon 14; #2 5’-GGAAGGTGGGGCGGCCTGGG-3’ against exon 2); TET2 (#1 5’-GGGAGATGTGAACTCTGGGA-3’ against exon 3; #2 5’-GGAGAACTTGCGCCTGTCAG-3’ against exon 7). Gene expression was determined with q-PCR. In some experiments, single clones of DNMT3A knockout cells were further selected with puromycin (Corning, NY; catalog number: 58-58-2; lot number: 61385051).

For dCas9-mediated targeting (Hilton et al., 2015; Kabadi et al., 2014), targeting sequences corresponding to sgRNAs were synthesized (GENEWIZ), and cloned into phU6-gRNA vector (Addgene; catalog number: 53188). The targeting sequences for CRP promoter were: #1 5’-GGGGACTGTTGTGGGGTGGG-3’; #2 5’-GAAGCTCTGACACCTGCCCC-3’. The catalytic domains of DNMT3A and TET2 were cloned into pcDNA-dCas9-p300 Core vector (Addgene, Cambridge, MA; catalog number: 61357). sgRNA vector and DNMT3A or TET2 vector were co-transfected into Hep3B cells. 48 hr later, gene expression was determined with q-PCR.

To prepare Hep3B cells stably expressing Cas9 (Koike-Yusa et al., 2014), pspax2, pMD2G and pLentiCas9-BFP were co-transfected into HEK293T cells. Lentivirus particles were harvested 48 hr later and were used to infect Hep3B cells. Stable cell line was selected with Blasticidine (Sigma-Aldrich; catalog number: 15205; lot number: BCBM5270V). Targeting sequences corresponding to sgRNAs were synthesized (GENEWIZ), cloned into pKLV-U6gRNA(BbsI)-PGKpuro2ABFP vector (Addgene; catalog number: 50946), and packed into lentivirus particles to infect Hep3B cells stably expressing Cas9. Stable cell lines of C/EBP-β knockout were further selected with puromycin (Corning, NY; catalog number: 58-58-2; lot number: 61385051). The targeting sequences for C/EBP-β were: #1 5’-GGGCGCCTGGGGGCCGCCAA-3’; #2 5’-GGCGGCGGCGGCGGCGGGGG-3’.

Luciferase reporter assay

Request a detailed protocol

The promoter fragment of CRP (−533 ~ +103 bp) was cloned into PGL4.10 (luc2) vector (Promega, Madison, WI; catalog number: E6651). Hep3B cells were transfected with 1.5 μg of PGL4.10 CRP reporter vector and 0.075 μg of phRL-TK (Promega; catalog number: E6241) using X-tremeGENE 9 DNA Transfection Reagent (Roche, Basel, Schweiz; catalog number: 06365787001; lot number: 23644700). After 48 hr of transfection, luciferase activities were measured using Dual-Luciferase Reporter Assay System (Promega; catalog number: E1960; lot number: 0000201344) on a Synergy HTX Multi-Mode Microplate Reader (BioTek, Winooski, VT). Activities of firefly luciferase were normalized with that of co-transfected Renilla luciferase.

Chromatin immunoprecipitation (ChIP)

Request a detailed protocol

ChIP experiments were performed as described (Nelson et al., 2006). Briefly, Hep3B cells with or without transfected PGL4.10 vector containing CRP promoter were cross-linked with 1.42% formaldehyde at room temperature for 15 min. The reaction was stopped by addition of glycine to a final concentration of 125 mM. Cells were then sonicated in IP buffer (150 mM NaCl, 50 mM Tris, pH 7.5, 5 mM EDTA, 0.5 % NP-40, 1.0% Triton X-100) at 4°C for 10 min, followed by addition of anti-STAT3 (Santa Cruz, Dallas, TX; catalog number: sc-482X; lot number: B0615), anti-p50 (Santa Cruz; catalog number: sc-7178X; lot number: C0314) or anti-C/EBP-β (Santa Cruz; catalog number: sc-150X; lot number: J2215) for 15 min in ice/water bath with sonification. Protein-DNA complexes were isolated with nProtein A Sepharose 4 Fast Flow (GE Healthcare, Chicago, IL; catalog number: 17-5280-01; lot number: 10235150), and eluted with 10% Chelex 100 (Sigma-Aldrich; catalog number: C7901; lot number: SLBM2735V). The eluates were treated with proteinase K (BioFroxx, Hesse Einhausen, Germany; catalog number:1124MG100; lot number: 86081) and subjected to DNA purification, and the crosslinking was reversed by heating at 55°C for 30 min and boiling for 10 min. DNA was then purified and analyzed with q-PCR. The primer sequences for human CRP used were: genomic binding (Forward: 5’-CTCTTCCCGAAGCTCTGACACCT-3’; Reverse: 5’-AACAGCTTCTCCATGGTCACGTC-3’); vector binding (Forward: 5’-CTCTTCCCGAAGCTCTGACACCT-3’; Reverse: 5’-TGGCTTTACCAACAGTACCGGAT-3’).

In some experiments, vectors were either entirely methylated with CpG methyltransferase (NEB, Ipswich, MA; catalog number: M0226L; lot number: 0311608) or site-specifically methylated at −53 or −108 CpG sites of CRP promoter through vector PCR using appropriately methylated primers before transfection.

Statistical analysis

Request a detailed protocol

Data were presented as mean ± SEM. Statistical analysis was performed by the two-tailed Student’s t-test, one-way ANOVA with Tukey post hoc or K-S tests as appropriate. Values of p<0.05 were considered significant.

Data availability

Sequencing data have been deposited in GEO under accession code GSE146797.

The following data sets were generated
The following previously published data sets were used
    1. Broad Institute
    (2012) NCBI Gene Expression Omnibus
    ID GSM916049. Bisulfite-Seq analysis of WGBS_Lib 11 derived from human liver cells.
    https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM916049
    1. UCSD AND SALK
    (2013) NCBI Gene Expression Omnibus
    ID GSM1120331. Whole Genome Shotgun Bisulfite Sequencing of Fat Cells from Human STL003.
    https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM1120331
    1. UCSD AND SALK
    (2013) NCBI Gene Expression Omnibus
    ID GSM1120325. Whole Genome Shotgun Bisulfite Sequencing of Adrenal Cells from Human STL003.
    https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc= GSM1120325
    1. UCSD AND SALK
    (2013) NCBI Gene Expression Omnibus
    ID GSM1120329. Whole Genome Shotgun Bisulfite Sequencing of Aorta Cells from Human STL003.
    https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM1120329
    1. UCSD AND SALK
    (2013) NCBI Gene Expression Omnibus
    ID GSM983649. Whole Genome Shotgun Bisulfite Sequencing of Esophagus Cells from Human STL003.
    https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM983649
    1. UCSD AND SALK
    (2013) NCBI Gene Expression Omnibus
    ID GSM1120333. Whole Genome Shotgun Bisulfite Sequencing of Gastric Cells from Human STL003.
    https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM1120333
    1. UCSD AND SALK
    (2013) NCBI Gene Expression Omnibus
    ID GSM983647. Whole Genome Shotgun Bisulfite Sequencing of Lung Cells from Human STL002.
    https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM983647
    1. UCSD AND SALK
    (2013) NCBI Gene Expression Omnibus
    ID GSM1120323. Whole Genome Shotgun Bisulfite Sequencing of Ovary Cells from Human STL002.
    https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM1120323
    1. UCSD AND SALK
    (2013) NCBI Gene Expression Omnibus
    ID GSM1010986. Whole Genome Shotgun Bisulfite Sequencing of Psoas Cells from Human STL003.
    https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM1010986
    1. UCSD AND SALK
    (2013) NCBI Gene Expression Omnibus
    ID GSM1120335. Whole Genome Shotgun Bisulfite Sequencing of Right Atrium Cells from Human STL003.
    https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM1120335
    1. UCSD AND SALK
    (2013) NCBI Gene Expression Omnibus
    ID GSM983645. Whole Genome Shotgun Bisulfite Sequencing of Sigmoid Colon Cells from Human STL001.
    https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM983645
    1. UCSD AND SALK
    (2013) NCBI Gene Expression Omnibus
    ID GSM983652. Whole Genome Shotgun Bisulfite Sequencing of Spleen Cells from Human STL003.
    https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM983652
    1. UCSD AND SALK
    (2013) NCBI Gene Expression Omnibus
    ID GSM1120322. Whole Genome Shotgun Bisulfite Sequencing of Thymus Cells from Human STL001.
    https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM1120322

References

    1. Ganapathi MK
    2. Schultz D
    3. Mackiewicz A
    4. Samols D
    5. Hu SI
    6. Brabenec A
    7. Macintyre SS
    8. Kushner I
    (1988)
    Heterogeneous nature of the acute phase response. Differential regulation of human serum amyloid A, C-reactive protein, and other acute phase proteins by cytokines in hep 3B cells
    Journal of Immunology 141:564–569.
    1. Ganapathi MK
    2. Rzewnicki D
    3. Samols D
    4. Jiang SL
    5. Kushner I
    (1991)
    Effect of combinations of cytokines and hormones on synthesis of serum amyloid A and C-reactive protein in hep 3B cells
    Journal of Immunology 147:1261–1265.

Decision letter

  1. Deborah Bourc'his
    Reviewing Editor; Institut Curie, France
  2. Jessica K Tyler
    Senior Editor; Weill Cornell Medicine, United States

In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

Acceptance summary:

The C reactive protein (CRP) belongs to the family of acute phase reactant genes, which play an essential role in inflammatory responses to infection or tissue injury in the liver. CPR needs to be quickly activated after stimulation by cytokines, and its activation is reversible upon resolution of inflammation. Zhang and colleagues report here that the dynamic expression of CPR is causally regulated by DNA methylation, and that this type of regulation may apply to other inducible genes that are endowed with CpG-poor promoters and have evolved CpG-containing binding sites for transcription factors specialized in rapid and reversible responses.

Decision letter after peer review:

Thank you for submitting your article "Reversible promoter methylation determines fluctuating expression of acute phase proteins" for consideration by eLife. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Jessica Tyler as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The interesting novelty and appeal of the study comes from 1) the biological importance of CRP and acute phase reactant genes in general, and 2) the details of CRP regulation in sequential phases by STAT3, NFkB and DNA demethylation/5OHT, and subsequent CEBP binding and activity. The evidence is supported by a satisfactory range of complementary experiments, from functional screens to modulation of DNA methylation by chemical inhibitors and knock-out or knock-down of methylating (DNMT3A) or demethylating (TET2) enzymes, with validations by targeted epigenomic editing.

However, the reviewers share the common concern that the manuscript is too concise in its current state to be fully instructive and convincing. More details are clearly required:

– In the Introduction, to provide proper background.

– In the Results section to explain the experimental design, methods and results and provide proper validation.

– In the Discussion, to replace the results in the current state of knowledge and clarify the model.

I agree that here is a need for further analyses of existing data and for inclusion of important missing controls to fully support interpretations and conclusions.

Please address the following comments in a revised version of your manuscript:

Essential revisions:

1) Provide information (in main text and figure legends) about i) how the CRISPR KO was performed: which exons were targeted? Was the analysis performed on single clones or cell bulk? And ii) how was DNA methylation analyzed in Figure 1: bisulfite sequencing? Available GEO datasets (and please cite the source if it is the case)?

2) Provide validation of TET2 and DNMT3A KO or KD by Western blot and RT-qPCR, respectively (as a supplementary figure).

3) Provide evidence that DNA methylation of the CRP promoter is directly changed in the experiments of functional modulation of DNA methylation (using DNA methylation inhibitors, DNMT3A and TET2 KO or KD). This is absolutely crucial for supporting conclusions. Along the same line, to further prove that the effect is not indirect, the expression of STAT3, p50 and C/EBP should be assessed (Western blot or RT-qPCR) in DNMT3A KO, TET2 KO and upon treatment with DNA methylation inhibitors.

4) Throughout the manuscript, figures illustrating methylation profiles are needed. In Figure 1F, please show raw bisulfite sequencing data with individual clones rather than fold differences between the two alleles-an unusual and incomplete way to show the data. This will benefit interpretation of differences between the 286A and 286C alleles (are most of the maintained CpGme (Figure 1G) on the A allele?). Also, please show WGBS tracks of the CRP gene in various human tissues (available from public databases) to see how many CpG sites of the CRP promoter are specifically hypomethylated in liver.

5) At the end of the manuscript, the authors investigate if demethylation of CpG-poor promoters is a general feature for the activation of APR genes, in cells and liver. This is important and potentially interesting but again, the authors need to provide much more details on what was done and to perform a more thorough analysis of their WGBS and RNA-seq data. Otherwise, Figure 7 is a too vague genomic characterization of CpG frequency and expression associations. How many replicates of RNA-seq and WGBS? Do replicates correlate? How many genes upregulated and what are the genes upregulated? Is CRP demethylated upon inflammation in the liver (genome browser views)? How do changes in expression and methylation correlate? How many DMRs and do they preferentially locate to CpG poor promoters? These are obvious questions that need to be addressed, possibly in supplementary figures.

6) To further support their assumption that APR genes may behave in general as CRP, it would be beneficial if the authors could look by RT-qPCR at expression of several of these genes in the +/- 5aza conditions (with cDNA from Figure 2A) to see if they go up, as they would predict. They could also include some gene sets based on PRG, CpG low status, etc… as well as known rapid response genes (see Hargreaves et al., 2009) that seem to be regulated in a very different manner than APR genes. These may be similar to the authors "cytokine" genes.

7) The sequential model proposed by the authors is confusing. First, according to Figure 4 and Figure 5B-D, all three TFs (STAT3, p50 and C/EBP) are potentially sensitive to DNA methylation, which contradicts the model. Second, to test which TF requires demethylation for binding, the kinetic experiments described in Figure 5B-D should be performed in TET2 KO cells (also generated by the authors) instead of DNMT3A KO cells, to determine which TF has reduced binding when demethylation is compromised.

8) There is a lack of thorough introduction and/or discussion of existing evidence from the literature to place the authors' study in the current knowledge context. First, it is known that dynamic DNA methylation changes usually affect CpG-poor promoters, in part due to lack of protective binding of methyl DNA binding proteins, while CpG islands (CGI) promoters, on the contrary, are predominantly non-methylated and stable to ensure expression of housekeeping genes and primary response genes (Hargreaves et al., 2009). Apart from the studies cited in the Discussion of this manuscript, acute changes in DNA methylation have been described in other contexts such as in neurons, upon activation (Guo et al., 2011 among others). As in the present study, but at a genome wide scale, the authors described dynamic reversible methylation of low density CpG promoters in brain-specific genes, and correlated them with gene expression. Moreover, CpG methylation is known to affect transcription factor binding (Yin et al., 2017), and specifically STAT3 binding (Thomas, 2012). And very recently, in neurons as well, TF were described to recruit TET1 to demethylate specific promoters upon neuronal activation (Sun et al., 2019). Second, in relationship with inflammation and APR gene regulation, the authors should discuss the work of Stephen Smale (Hargreaves et al., 2009) -and potentially others- about conventional categorization of CpG-rich promoters in inflammatory gene induction: nucleosome poor promoters, accessible, independent of remodeling, one step induction. This provides an interesting contrast with the sequential kinetics of CRP, regulated in part by changes in DNA methylation and temporal waves of TF binding, as demonstrated here by the authors.

Recommended changes:

1) Why is CRP hypomethylated in liver cells in unstimulated conditions? Is it because a basal level of expression is needed? This could be discussed.

2) In Figure 2A, the authors show that DNA methylation inhibitors enhance CRP expression at the resting stage. However, they did not assess as to whether CRP expression is modified by these inhibitors after induction (it should not), while this would be an important point for their demonstration. Please include this analysis after Figure 2A.

3) To assess whether DNA demethylation precedes or follows gene activation, please add a 24h time point for DNA methylation analysis (Figure 1G), if possible.

https://doi.org/10.7554/eLife.51317.sa1

Author response

Essential revisions:

1) Provide information (in main text and figure legends) about i) how the CRISPR KO was performed: which exons were targeted? Was the analysis performed on single clones or cell bulk? And ii) how was DNA methylation analyzed in Figure 1: bisulfite sequencing? Available GEO datasets (and please cite the source if it is the case)?

In CRISPR KO experiments, exon 3 or 7 of TET2 and exon 14 or 2 of DNMT3A were targeted. The analysis was performed on cell bulk in Figure 3 and 5, and was performed on single clones in Figure 6.

In Figure 1C, DNA methylation levels of CRP promoter in different human tissues were obtained from available GEO datasets generated by whole-genome bisulfite sequencing: Liver 01-GSM916049, Liver 02-GSM1716965, Adipose-GSM1120331, Adrenal-GSM1120325, Aorta-GSM1120329, Esophagus-GSM983649, Gaster-GSM1120333, Lung-GSM983647, Ovary-GSM1120323, Muscle-GSM1010986, Atrium-GSM1120335, Colon-GSM983645, Spleen-GSM983652, Thymus-GSM1120322. In other figures of Figure 1, DNA methylation levels of CRP promoter were determined with bisulfite cloning sequencing.

These descriptions have been included in the revised manuscript.

2) Provide validation of TET2 and DNMT3A KO or KD by Western blot and RT-qPCR, respectively (as a supplementary figure).

Immunoblotting and qPCR validation of TET2/DNMT3A KD/KO showed that the levels of TET2 or DNMT3A were effectively reduced (Figure 3—figure supplement 2).

3) Provide evidence that DNA methylation of the CRP promoter is directly changed in the experiments of functional modulation of DNA methylation (using DNA methylation inhibitors, DNMT3A and TET2 KO or KD). This is absolutely crucial for supporting conclusions. Along the same line, to further prove that the effect is not indirect, the expression of STAT3, p50 and C/EBP should be assessed (Western blot or RT-qPCR) in DNMT3A KO, TET2 KO and upon treatment with DNA methylation inhibitors.

We have performed additional experiments as suggested by the editor and reviewers. We have assessed the changes in DNA methylation of CRP promoter in Hep3B cells following treatment with DNA methylation inhibitor 5-aza, or DNMT3A/TET2 KD/KO. The results indicated that 5-aza and DNMT3A KD/KO reduced, whereas TET2 KD/KO augmented DNA methylation of CRP promoter (Figure 2—figure supplement 1 and Figure 3—figure supplement 1).

We have assessed the expression of STAT3, p50 and C/EBP-β in Hep3B cells following treatment with 5-aza, or DNMT3A/TET2 KD/KO (Figure 3—figure supplement 3). 5-aza treatment reduced the expression of STAT3, but did not affect that of p50 and C/EBP-β. DNMT3A or TET2 KD showed little effect on the expression of the three TFs. DNMT3A or TET2 KO tended to reduce their expression. Because the observed effects on CRP expression by 5-aza or DNMT3A/TET2 KD/KO are consistent or complementary, the above results suggest that these manipulations regulate CRP expression by directly modulating promoter methylation.

Further support to this suggestion is provided by specifically modulating promoter methylation of CRP via dCas9-mediated targeting of the catalytic domains of DNMT3A or TET2. Enforced methylation of CRP promoter by DNMT3A-dCas9 reduced the expression of CRP in Hep3B cells, but showed little effect on that of serum amyloid A (SAA, another major human APR) and serum amyloid P component (SAP, a paralog of CRP) (Figure 3F). By contrast, enforced demethylation of CRP promoter by TET2-dCas9 only selectively enhanced the expression of CRP (Figure 3G). We thus conclude that DNMT3A and TET2-tuned methylation status of CRP promoter constitutes a key part of the regulatory mechanism that causally determines the expression.

4) Throughout the manuscript, figures illustrating methylation profiles are needed. In Figure 1F, please show raw bisulfite sequencing data with individual clones rather than fold differences between the two alleles-an unusual and incomplete way to show the data. This will benefit interpretation of differences between the 286A and 286C alleles (are most of the maintained CpGme (Figure 1G) on the A allele?). Also, please show WGBS tracks of the CRP gene in various human tissues (available from public databases) to see how many CpG sites of the CRP promoter are specifically hypomethylated in liver.

Figure 1 has been carefully revised according to the comments of the editor and reviewers. Raw bisulfite sequencing data with individual clones are shown in Figure 1F. The results indicate that most maintained CpGme were on -286C allele. The WGBS tracks of CRP gene are shown in Figure 1C. -53, -108, -286 and -306CpG of CRP are all most demethylated in human livers with only -255CpG in Liver 01 being more methylated than in Adrenal.

5) At the end of the manuscript, the authors investigate if demethylation of CpG-poor promoters is a general feature for the activation of APR genes, in cells and liver. This is important and potentially interesting but again, the authors need to provide much more details on what was done and to perform a more thorough analysis of their WGBS and RNA-seq data. Otherwise, Figure 7 is a too vague genomic characterization of CpG frequency and expression associations. How many replicates of RNA-seq and WGBS? Do replicates correlate? How many genes upregulated and what are the genes upregulated? Is CRP demethylated upon inflammation in the liver (genome browser views)? How do changes in expression and methylation correlate? How many DMRs and do they preferentially locate to CpG poor promoters? These are obvious questions that need to be addressed, possibly in supplementary figures.

We have performed additional experiments and analysis as suggested by the editor and reviewers.

Two biological replicates were examined for both RNA-seq and WGBS. For RNA-seq, the correlations (R2) between the replicates are 0.991 for resting Hep3B cells, 0.998 for induced Hep3B cells, 0.884 for resting mouse livers and 0.803 for induced mouse livers (Figure 7—figure supplement 1A and B). For WGBS, the correlations (R2) between the replicates are 0.828 for resting mouse livers and 0.810 for induced mouse livers (Figure 7—figure supplement 1C).

The expression of 2705 and 3371 genes were changed by over 2-fold (up- and down-regulated) in induced Hep3B cells and in induced mouse livers, respectively. In Hep3B cells, the “regulation of inflammatory response”, “acute inflammatory response” and “regulation of immune effector process” are the top 3 activated biological processes. In induced mouse livers, the “acute inflammatory response”, “positive regulation of response to external stimulus” and “cell chemotaxis” are the top 3 activated biological processes (Figure 7—figure supplement 1D and E).

In contrast to human CRP, mouse CRP is not an acute phase protein [1-3] (possibly due to the loss of binding sites for C/EBP-β as revealed by bioinformatics analysis), and its promoter did not undergo demethylation in induced livers (Author response image 1). Although genes with CpG-poor promoters tended to show greater changes in both expression and methylation (Figure 7D and 7E), changes in expression and promoter methylation per se did not show significant correlation. These would suggest that promoter methylation and gene expression may be qualitatively but not quantitatively associated with each other.

Overall, 1262 differentially methylated regions (DMR; 1k sequence window) were identified in induced versus resting mouse livers. The CpG ratios of these DMRs (median: 0.07; 25th~75th percentile: 0.04~0.17) are significantly lower than that of non-DMRs (median: 0.16; 25th~75th percentile: 0.11~0.23; p < 10-15). Therefore, differential methylation prefers to occur in CpG-poor regions. However, there are only 85 promoters located in these DMRs. Such an under-representation is consistent with previous findings made in mouse neurons activated by electroconvulsive stimulation 4.

Author response image 1
Download asset Open asset
The bisulfite sequencing tracks of Nxpe5 (Log2(FC of expression) = 3.6), Cyp4a14 (Log2(FC of expression) = -3.1), Clec4n (Log2(FC of expression) = 1.9) and CRP (Log2(FC of expression) = 0.8).

Promoter CpGs are boxed by red rectangles.

6) To further support their assumption that APR genes may behave in general as CRP, it would be beneficial if the authors could look by RT-qPCR at expression of several of these genes in the +/- 5aza conditions (with cDNA from Figure 2A) to see if they go up, as they would predict. They could also include some gene sets based on PRG, CpG low status, etc… as well as known rapid response genes (see Hargreaves et al., 2009) that seem to be regulated in a very different manner than APR genes. These may be similar to the authors "cytokine" genes.

We have performed additional experiments as suggested by the editor and reviewers. The effects of 5-aza treatment on the expression of 2 additional APRs with CpG-poor promoters, 3 class A PRGs with CpG-rich promoters, 4 class B PRGs with CpG-poor promoters, and 2 class B SRG with CpG-poor promoters in Hep3B cells were determined with q-PCR (Author response image 2). 5-aza treatment significantly enhanced most of the examined genes with CpG-poor promoters but not those with CpG-rich promoters. Therefore, PRGs with CpG-rich promoters are likely induced by mechanisms independent of promoter methylation.

Author response image 2
Download asset Open asset
Expression of 2 additional APRs with CpG-poor promoters (SAA and LIF), 3 class A PRGs with CpG-rich promoters (CXCL2, Nfkbia, Pim1), 4 class B PRGs with CpG-poor promoters (TNF, CSF2, IL1b, IL23a), and 2 class B SRG with CpG-poor promoters (LCN2 and MX2) in Hep3B cells treated with or without 5-aza for 36 h.

Of note, TNF has been classified as a Class A PRG in mouse macrophages 5. However, the observed/expected CpG ratio of TNF promoter in human genome is 0.31, we thus classified it as a class B PRG here.

7) The sequential model proposed by the authors is confusing. First, according to Figure 4 and Figure 5B-D, all three TFs (STAT3, p50 and C/EBP) are potentially sensitive to DNA methylation, which contradicts the model. Second, to test which TF requires demethylation for binding, the kinetic experiments described in Figure 5B-D should be performed in TET2 KO cells (also generated by the authors) instead of DNMT3A KO cells, to determine which TF has reduced binding when demethylation is compromised.

We have performed additional experiments as suggested by the editor and reviewers. TET2 KO almost abrogated the recruitment of p50 and C/EBP-β to CRP promoter, but the recruitment of STAT3 was still apparent (Figure 5A-D). This indicates that STAT3 can nevertheless be recruited to CRP promoter even when demethylation is compromised, consistent with the observations that vector binding of STAT3 was least sensitive to methylation (Figure 4B and C). This also indicates that STAT3 can act largely independent of p50 and C/EBP-β to drive CRP expression, albeit markedly impaired (Figure 5A). Indeed, the sole activation of STAT3 in wildtype cells drove CRP expression to a level comparable to the minor peak, whereas the sole activation of NF-κB was completely ineffective (Figure 5E). NF-κB inhibition (with intact STAT3) at the induced state, however, resulted in an even stronger methylation of CRP promoter (Figure 5F) and a reversal of allelic imbalance (Figure 5G). Therefore, promoter demethylation requires p50 that acts downstream of STAT3.

Interestingly, enforced DNA demethylation by DNMT3A KO not only tripled CRP expression during the entire course of induction, but eliminated the time lag between the two waves (Figure 5A). The augmented amplitude can be explained by enhanced recruitment of three TFs, while the altered dynamics may correspond to the shifted timing of p50 recruitment (Figure 5B-D). As such, p50 selectively recruited during the time lag could be responsible for promoter demethylation to prime the second wave. Accordingly, C/EBP-β appears to be the major effector that responds to promoter demethylation: its overexpression did not demethylate CRP promoter (Figure 5H and I), but when combined with blockage of DNA methylation, it drove the resting expression of CRP to a level approaching to that induced by IL-6 and IL-1β (Figure 5J). C/EBP-β KO, however, lowered the induced expression of CRP by ~70% (Figure 5K). These results together are consistent with the proposed sequential model.

We have carefully revised the manuscript to elaborate the sequential model.

8) There is a lack of thorough introduction and/or discussion of existing evidence from the literature to place the authors' study in the current knowledge context. First, it is known that dynamic DNA methylation changes usually affect CpG-poor promoters, in part due to lack of protective binding of methyl DNA binding proteins, while CpG islands (CGI) promoters, on the contrary, are predominantly non-methylated and stable to ensure expression of housekeeping genes and primary response genes (Hargreaves et al., 2009). Apart from the studies cited in the Discussion of this manuscript, acute changes in DNA methylation have been described in other contexts such as in neurons, upon activation (Guo et al., 2011 among others). As in the present study, but at a genome wide scale, the authors described dynamic reversible methylation of low density CpG promoters in brain-specific genes, and correlated them with gene expression. Moreover, CpG methylation is known to affect transcription factor binding (Yin et al., 2017), and specifically STAT3 binding (Thomas, 2012). And very recently, in neurons as well, TF were described to recruit TET1 to demethylate specific promoters upon neuronal activation (Sun et al., 2019). Second, in relationship with inflammation and APR gene regulation, the authors should discuss the work of Stephen Smale (Hargreaves et al., 2009) -and potentially others- about conventional categorization of CpG-rich promoters in inflammatory gene induction: nucleosome poor promoters, accessible, independent of remodeling, one step induction. This provides an interesting contrast with the sequential kinetics of CRP, regulated in part by changes in DNA methylation and temporal waves of TF binding, as demonstrated here by the authors.

The manuscript has been carefully revised according to the comments of the editor and reviewers.

Acute changes in DNA methylation have also been analyzed at a genome-wide scale in previous studies. One study examined mouse neurons activated by electroconvulsive stimulation, and found that methylation changes were preferentially occurred in CpG-poor regions [4]. Though promoters were underrepresented in these regions, their methylation changes were nevertheless modestly anticorrelated with gene expression [4]. Such CpG content-dependent changes in DNA methylation, however, were not observed in another study examining neurons activated by contextual learning [6]. Moreover, DNA methylation changes in human dendritic cells following infection rarely occurred at promoters [7, 8], and were claimed to be a consequence of gene expression [7]. Those findings thus argue that the regulation of reversible methylation on inducible expression of genes with CpG-poor promoters may be context-dependent, and that rigorously controlled case study should be integrated into genome-wide investigation to conclude on causality.

Interestingly, genes showing inducible expression in macrophages activated by endotoxin have been classified into two groups: nucleosome remodeling-independent genes with CpG-rich promoters, and nucleosome remodeling-dependent genes with CpG-poor promoters [5]. Despite their distinct requirements for SWI/SNF complexes [5], preassembled Pol II [9] and new protein synthesis [5, 9, 10], both groups of genes exhibit a single-wave kinetics of induction [5, 9, 10]. This is in contrast with CRP and probably other major APRs, which show a two-wave kinetics of induction with the second wave licensed by promoter demethylation. However, nucleosome remodeling may also act downstream in the second wave, as C/EBP-β has recently been shown to promote CRP expression by recruiting BRG1 via MKL1 [11]. Conversely, promoter methylation may also contribute to inducible expression of nucleosome remodeling-dependent genes in macrophages by directly regulating TF recruitment [12-14].

Despite that most CpGs in mammalian promoters not associated with CGIs are usually methylated [15, 16], TETs and DNMTs can nevertheless mediate active demethylation and de novomethylation, respectively. This indicates that the methylation status of part of the genome may depend on the balance of the two types of enzymes [15-19]. Cellular signaling able to tip the balance of TETs and DNMTs could thus represent a regulatory mechanism that finely and reversibly tunes the expression of certain genes in response to environmental cues. In case of CRP, DNMT3A and TET2 appear to be involved in the regulation. Though the mechanism of TF-induced local demethylation is not fully understood [16], TFs including NF-κB and EGR1 have been reported to evoke DNA demethylation in neurons [20] for example by recruiting TET1 [21]. Future study is warranted to elucidate how TFs regulate the balance of TETs and DNMTs and to discover scenarios where regulation by reversible DNA methylation plays a prominent role.

These discussions have been included in the revised manuscript.

Recommended changes:

1) Why is CRP hypomethylated in liver cells in unstimulated conditions? Is it because a basal level of expression is needed? This could be discussed.

As pointed by the editor and reviewers, hepatocytes secrete CRP in unstimulated conditions, yielding a basal circulating level of about 1~3 μg/ml in apparently healthy individuals [22-24]. CRP has been proposed to act as a soluble pattern recognition receptor in host defense [25, 26]. Therefore, basal levels of circulating CRP may constitute an integral part of immune surveillance that contributes to the silent clearance of invading pathogens and apoptotic cells in homeostasis. These discussions have been included in the revised manuscript.

2) In Figure 2A, the authors show that DNA methylation inhibitors enhance CRP expression at the resting stage. However, they did not assess as to whether CRP expression is modified by these inhibitors after induction (it should not), while this would be an important point for their demonstration. Please include this analysis after Figure 2A.

We have performed additional experiments as suggested by the editor and reviewers. Treating Hep3B cells with 5-aza significantly enhanced CRP expression at the resting but not at the induced state (Figure 2A) wherein CRP promoter underwent active demethylation (Figure 1G).

3) To assess whether DNA demethylation precedes or follows gene activation, please add a 24h time point for DNA methylation analysis (Figure 1G), if possible.

This experiment was originally arranged to be performed following those assessing methylation changes induced by 5-aza, TET/DNMT KO or KD (Figure II). Before its completion, however, our lab had to be closed due to the SARS-CoV-2 epidemic. Therefore, we could not arrange this experiment in a reasonable time frame. Nevertheless, the results shown in Figure 5 suggest that the demethylation of CRP promoter might follow the minor peak driven by STAT3, but precede the major peak driven by C/EBP-β.

References:

1) Baltz ML, de Beer FC, Feinstein A, Munn EA, Milstein CP, Fletcher TC, March JF, Taylor J, Bruton C, Clamp JR, Davies AJ, Pepys MB. Phylogenetic aspects of c-reactive protein and related proteins. Ann N Y Acad Sci. 1982;389:49-75

2) Pepys MB, Hirschfield GM. C-reactive protein: A critical update. J Clin Invest. 2003;111:1805-1812

3) Pathak A, Agrawal A. Evolution of c-reactive protein. Front Immunol. 2019;10:943

4) Guo JU, Ma DK, Mo H, Ball MP, Jang MH, Bonaguidi MA, Balazer JA, Eaves HL, Xie B, Ford E, Zhang K, Ming GL, Gao Y, Song H. Neuronal activity modifies the DNA methylation landscape in the adult brain. Nat Neurosci. 2011;14:1345-1351

5) Ramirez-Carrozzi VR, Braas D, Bhatt DM, Cheng CS, Hong C, Doty KR, Black JC, Hoffmann A, Carey M, Smale ST. A unifying model for the selective regulation of inducible transcription by cpg islands and nucleosome remodeling. Cell. 2009;138:114-128

6) Halder R, Hennion M, Vidal RO, Shomroni O, Rahman RU, Rajput A, Centeno TP, van Bebber F, Capece V, Garcia Vizcaino JC, Schuetz AL, Burkhardt S, Benito E, Navarro Sala M, Javan SB, Haass C, Schmid B, Fischer A, Bonn S. DNA methylation changes in plasticity genes accompany the formation and maintenance of memory. Nat Neurosci. 2016;19:102-110

7) Pacis A, Mailhot-Leonard F, Tailleux L, Randolph HE, Yotova V, Dumaine A, Grenier JC, Barreiro LB. Gene activation precedes DNA demethylation in response to infection in human dendritic cells. Proc Natl Acad Sci U S A. 2019;116:6938-6943

8) Pacis A, Tailleux L, Morin AM, Lambourne J, MacIsaac JL, Yotova V, Dumaine A, Danckaert A, Luca F, Grenier JC, Hansen KD, Gicquel B, Yu M, Pai A, He C, Tung J, Pastinen T, Kobor MS, Pique-Regi R, Gilad Y, Barreiro LB. Bacterial infection remodels the DNA methylation landscape of human dendritic cells. Genome Res. 2015;25:1801-1811

9) Hargreaves DC, Horng T, Medzhitov R. Control of inducible gene expression by signal-dependent transcriptional elongation. Cell. 2009;138:129-145

10) Ramirez-Carrozzi VR, Nazarian AA, Li CC, Gore SL, Sridharan R, Imbalzano AN, Smale ST. Selective and antagonistic functions of swi/snf and mi-2beta nucleosome remodeling complexes during an inflammatory response. Genes Dev. 2006;20:282-296

11) Fan Z, Li N, Xu Z, Wu J, Fan X, Xu Y. An interaction between mkl1, brg1, and c/ebpbeta mediates palmitate induced crp transcription in hepatocytes. Biochim Biophys Acta Gene Regul Mech. 2019;1862:194412

12) Thomas RM, Sai H, Wells AD. Conserved intergenic elements and DNA methylation cooperate to regulate transcription at the il17 locus. J Biol Chem. 2012;287:25049-25059

13) Hu S, Wan J, Su Y, Song Q, Zeng Y, Nguyen HN, Shin J, Cox E, Rho HS, Woodard C, Xia S, Liu S, Lyu H, Ming GL, Wade H, Song H, Qian J, Zhu H. DNA methylation presents distinct binding sites for human transcription factors. ELife. 2013;2:e00726

14) Yin Y, Morgunova E, Jolma A, Kaasinen E, Sahu B, Khund-Sayeed S, Das PK, Kivioja T, Dave K, Zhong F, Nitta KR, Taipale M, Popov A, Ginno PA, Domcke S, Yan J, Schubeler D, Vinson C, Taipale J. Impact of cytosine methylation on DNA binding specificities of human transcription factors. Science. 2017;356

15) Wu H, Zhang Y. Reversing DNA methylation: Mechanisms, genomics, and biological functions. Cell. 2014;156:45-68

16) Luo C, Hajkova P, Ecker JR. Dynamic DNA methylation: In the right place at the right time. Science. 2018;361:1336-1340

17) Jones PA. Functions of DNA methylation: Islands, start sites, gene bodies and beyond. Nat Rev Genet. 2012;13:484-492

18) Dor Y, Cedar H. Principles of DNA methylation and their implications for biology and medicine. Lancet. 2018;392:777-786

19) Blattler A, Farnham PJ. Cross-talk between site-specific transcription factors and DNA methylation states. J Biol Chem. 2013;288:34287-34294

20) Jarome TJ, Butler AA, Nichols JN, Pacheco NL, Lubin FD. Nf-kappab mediates gadd45beta expression and DNA demethylation in the hippocampus during fear memory formation. Front Mol Neurosci. 2015;8:54

21) Sun Z, Xu X, He J, Murray A, Sun MA, Wei X, Wang X, McCoig E, Xie E, Jiang X, Li L, Zhu J, Chen J, Morozov A, Pickrell AM, Theus MH, Xie H. Egr1 recruits tet1 to shape the brain methylome during development and upon neuronal activity. Nat Commun. 2019;10:3892

22) Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of c-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565

23) Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397

24) Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated c-reactive protein and ischemic vascular disease. N Engl J Med. 2008;359:1897-1908

25) Bottazzi B, Doni A, Garlanda C, Mantovani A. An integrated view of humoral innate immunity: Pentraxins as a paradigm. Annu Rev Immunol. 2010;28:157-183

26) Du Clos TW. Pentraxins: Structure, function, and role in inflammation. ISRN Inflamm. 2013;2013:379040

https://doi.org/10.7554/eLife.51317.sa2

Article and author information

Author details

  1. Shi-Chao Zhang

    MOE Key Laboratory of Cell Activities and Stress Adaptations, School of Life Sciences, Lanzhou University, Lanzhou, China
    Contribution
    Investigation, Writing - review and editing
    Contributed equally with
    Ming-Yu Wang and Jun-Rui Feng
    Competing interests
    No competing interests declared

  2. Ming-Yu Wang

    MOE Key Laboratory of Cell Activities and Stress Adaptations, School of Life Sciences, Lanzhou University, Lanzhou, China
    Contribution
    Investigation, Writing - review and editing
    Contributed equally with
    Shi-Chao Zhang and Jun-Rui Feng
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6622-5996

  3. Jun-Rui Feng

    MOE Key Laboratory of Environment and Genes Related to Diseases, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, China
    Contribution
    Investigation, Writing - review and editing
    Contributed equally with
    Shi-Chao Zhang and Ming-Yu Wang
    Competing interests
    No competing interests declared

  4. Yue Chang

    MOE Key Laboratory of Cell Activities and Stress Adaptations, School of Life Sciences, Lanzhou University, Lanzhou, China
    Contribution
    Investigation, Writing - review and editing
    Competing interests
    No competing interests declared

  5. Shang-Rong Ji

    MOE Key Laboratory of Cell Activities and Stress Adaptations, School of Life Sciences, Lanzhou University, Lanzhou, China
    Contribution
    Supervision, Funding acquisition, Writing - original draft
    For correspondence
    jsr@lzu.edu.cn
    Competing interests
    No competing interests declared

  6. Yi Wu

    MOE Key Laboratory of Environment and Genes Related to Diseases, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, China
    Contribution
    Supervision, Funding acquisition, Writing - original draft
    For correspondence
    wuy@lzu.edu.cn
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0365-5590

Funding

National Natural Science Foundation of China (31671339)

  • Yi Wu

National Natural Science Foundation of China (31870767)

  • Yi Wu

National Natural Science Foundation of China (31570749)

  • Shang-Rong Ji

National Natural Science Foundation of China (31770819)

  • Shang-Rong Ji

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

We thank the Core Facility of School of Life Sciences, Lanzhou University for technical and instrumental support.

Ethics

Animal experimentation: The experiments conformed to the Guide for the Care and Use of Laboratory Animals published by NIH, and were conducted according to the protocols approved by the Ethics Committee of Animal Experiments of Xi'an Jiaotong University and Lanzhou University.

Senior Editor

  1. Jessica K Tyler, Weill Cornell Medicine, United States

Reviewing Editor

  1. Deborah Bourc'his, Institut Curie, France

Publication history

  1. Received: August 25, 2019
  2. Accepted: March 27, 2020
  3. Accepted Manuscript published: March 30, 2020 (version 1)
  4. Version of Record published: April 6, 2020 (version 2)

Copyright

© 2020, Zhang et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,325
    Page views
  • 170
    Downloads
  • 9
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Shi-Chao Zhang
  2. Ming-Yu Wang
  3. Jun-Rui Feng
  4. Yue Chang
  5. Shang-Rong Ji
  6. Yi Wu
(2020)
Reversible promoter methylation determines fluctuating expression of acute phase proteins
eLife 9:e51317.
https://doi.org/10.7554/eLife.51317

Categories and tags

Research organism

Further reading

    1. Immunology and Inflammation

    PTPN22 R620W gene editing in T cells enhances low-avidity TCR responses

    Warren Anderson, Fariba Barahmand-pour-Whitman ... David J Rawlings
    Research Article Updated

    A genetic variant in the gene PTPN22 (R620W, rs2476601) is strongly associated with increased risk for multiple autoimmune diseases and linked to altered TCR regulation and T cell activation. Here, we utilize Crispr/Cas9 gene editing with donor DNA repair templates in human cord blood-derived, naive T cells to generate PTPN22 risk edited (620W), non-risk edited (620R), or knockout T cells from the same donor. PTPN22 risk edited cells exhibited increased activation marker expression following non-specific TCR engagement, findings that mimicked PTPN22 KO cells. Next, using lentiviral delivery of T1D patient-derived TCRs against the pancreatic autoantigen, islet-specific glucose-6 phosphatase catalytic subunit-related protein (IGRP), we demonstrate that loss of PTPN22 function led to enhanced signaling in T cells expressing a lower avidity self-reactive TCR, but not a high-avidity TCR. In this setting, loss of PTPN22 mediated enhanced proliferation and Th1 skewing. Importantly, expression of the risk variant in association with a lower avidity TCR also increased proliferation relative to PTPN22 non-risk T cells. Together, these findings suggest that, in primary human T cells, PTPN22 rs2476601 contributes to autoimmunity risk by permitting increased TCR signaling and activation in mildly self-reactive T cells, thereby potentially expanding the self-reactive T cell pool and skewing this population toward an inflammatory phenotype.

    1. Immunology and Inflammation

    Human thymopoiesis produces polyspecific CD8+ α/β T cells responding to multiple viral antigens

    Valentin Quiniou, Pierre Barennes ... David Klatzmann
    Research Article

    T-cell receptors (TCRs) are formed by stochastic gene rearrangements, theoretically generating >1019 sequences. They are selected during thymopoiesis, which releases a repertoire of about 108 unique TCRs per individual. How evolution shaped a process that produces TCRs that can effectively handle a countless and evolving set of infectious agents is a central question of immunology. The paradigm is that a diverse enough repertoire of TCRs should always provide a proper, though rare, specificity for any given need. Expansion of such rare T cells would provide enough fighters for an effective immune response and enough antigen-experienced cells for memory. We show here that human thymopoiesis releases a large population of clustered CD8+ T cells harboring α/β paired TCRs that (i) have high generation probabilities and (ii) a preferential usage of some V and J genes, (iii) which CDR3 are shared between individuals, and (iv) can each bind and be activated by multiple unrelated viral peptides, notably from EBV, CMV, and influenza. These polyspecific T cells may represent a first line of defense that is mobilized in response to infections before a more specific response subsequently ensures viral elimination. Our results support an evolutionary selection of polyspecific α/β TCRs for broad antiviral responses and heterologous immunity.

    1. Immunology and Inflammation

    A lncRNA identifies Irf8 enhancer element in negative feedback control of dendritic cell differentiation

    Huaming Xu, Zhijian Li ... Martin Zenke
    Research Article Updated

    Transcription factors play a determining role in lineage commitment and cell differentiation. Interferon regulatory factor 8 (IRF8) is a lineage determining transcription factor in hematopoiesis and master regulator of dendritic cells (DC), an important immune cell for immunity and tolerance. IRF8 is prominently upregulated in DC development by autoactivation and controls both DC differentiation and function. However, it is unclear how Irf8 autoactivation is controlled and eventually limited. Here, we identified a novel long non-coding RNA transcribed from the +32 kb enhancer downstream of Irf8 transcription start site and expressed specifically in mouse plasmacytoid DC (pDC), referred to as lncIrf8. The lncIrf8 locus interacts with the lrf8 promoter and shows differential epigenetic signatures in pDC versus classical DC type 1 (cDC1). Interestingly, a sequence element of the lncIrf8 promoter, but not lncIrf8 itself, is crucial for mouse pDC and cDC1 differentiation, and this sequence element confers feedback inhibition of Irf8 expression. Taken together, in DC development Irf8 autoactivation is first initiated by flanking enhancers and then second controlled by feedback inhibition through the lncIrf8 promoter element in the +32 kb enhancer. Our work reveals a previously unrecognized negative feedback loop of Irf8 that orchestrates its own expression and thereby controls DC differentiation.